Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

aTYR PHARMA (ATYR) Total Current Liabilities (2019 - 2025)

aTYR PHARMA's Total Current Liabilities history spans 7 years, with the latest figure at $15.1 million for Q4 2025.

  • For Q4 2025, Total Current Liabilities rose 1.21% year-over-year to $15.1 million; the TTM value through Dec 2025 reached $15.1 million, up 1.21%, while the annual FY2025 figure was $15.1 million, 1.21% up from the prior year.
  • Total Current Liabilities reached $15.1 million in Q4 2025 per ATYR's latest filing, down from $15.7 million in the prior quarter.
  • In the past five years, Total Current Liabilities ranged from a high of $16.4 million in Q4 2023 to a low of $4.5 million in Q1 2021.
  • Average Total Current Liabilities over 5 years is $11.7 million, with a median of $12.6 million recorded in 2023.
  • Peak YoY movement for Total Current Liabilities: plummeted 57.39% in 2021, then soared 130.53% in 2022.
  • A 5-year view of Total Current Liabilities shows it stood at $6.0 million in 2021, then skyrocketed by 130.53% to $13.9 million in 2022, then increased by 18.42% to $16.4 million in 2023, then fell by 8.83% to $15.0 million in 2024, then grew by 1.21% to $15.1 million in 2025.
  • Per Business Quant, the three most recent readings for ATYR's Total Current Liabilities are $15.1 million (Q4 2025), $15.7 million (Q3 2025), and $15.5 million (Q2 2025).